Allied Blenders Eyes Premium Growth with ₹1,000 Cr QIP, Faces Bihar & Capex Hurdles

CONSUMER-PRODUCTS
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Allied Blenders Eyes Premium Growth with ₹1,000 Cr QIP, Faces Bihar & Capex Hurdles
Overview

Allied Blenders and Distillers (ABD) aims to boost revenue from premium and above (P&A) categories to 70-75% within two years, up from 55%. The company reported ₹2,201.17 crore net profit for FY26 and approved a ₹1,000 crore Qualified Institutional Placement (QIP) for significant capital spending, including a new Andhra Pradesh plant and supply chain upgrades. Despite a 'Strong Buy' analyst consensus and awards for its subsidiary ABD Maestro, ABD faces challenges from its valuation, regulatory uncertainty in Bihar, and rising input costs pressuring margins.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Ambitious Premium Push

Allied Blenders and Distillers (ABD) is making a strong push into premium and above (P&A) spirits, backed by solid financials and a plan for significant capital investment to reshape its market standing. The close of fiscal year 2025-26 provides a clear view of the company's performance and profitability, setting the stage for its aggressive growth plans.

Boosting Premium Sales and Funding Expansion

ABD is strategically shifting its revenue mix, aiming for premium and above (P&A) categories to contribute 70-75% of revenue within two years, up from 55%. This is key for value growth, as premium products already deliver 55% of revenue from just 47% of volume. The company reported a consolidated net profit of ₹2,201.17 crore for fiscal year 2025-26. To fund this premium drive and expansion, ABD has approved a Qualified Institutional Placement (QIP) to raise up to ₹1,000 crore. These funds are designated for significant supply chain investments, including a new 200,000-litre-per-day plant in Andhra Pradesh and improved bottling capacity in Punjab. These upgrades aim to boost productivity and secure the supply chain. ABD Maestro, the luxury subsidiary, continues to earn awards, validating the premium strategy.

Valuation and Competitor Landscape

ABD is trading at a premium valuation, with a Price-to-Earnings (P/E) ratio of around 58-60x as of May 2026. This compares to direct competitors United Spirits at roughly 53-54x and Radico Khaitan at 77-78x. The overall Indian spirits sector trades at a P/E of about 28.87x. ABD's market value was approximately ₹15,683 crore as of May 12, 2026, indicating strong investor expectations for future growth based on its valuation multiples. Major domestic competitors include United Spirits (market cap ~₹92,555 Cr) and Radico Khaitan (market cap ~₹46,198 Cr). Despite strong recent stock performance (e.g., +73.08% over the past year), ABD's historical revenue growth has lagged the industry median, raising questions about its capacity to gain market share faster than rivals.

Investing in Future Growth and Backward Integration

Strategic investments also include building warehousing capacity for ABD's planned entry into India's single malt market by FY29. The new facility in Andhra Pradesh, managed by subsidiary Keyan Blenders, will produce Extra Neutral Alcohol (ENA) and fuel-grade ethanol, alongside a new bottling unit. This move toward backward integration is a defensive measure aimed at protecting and growing profit margins in a highly competitive, cost-sensitive market. ABD Maestro's expanding portfolio, featuring award-winning brands, shows a focused effort to capture the high-value luxury segment, operating as a nimble startup within ABD's broader business.

Key Risks and Challenges

ABD's aggressive expansion strategy faces considerable risks. The uncertain regulatory future of Bihar, which previously accounted for about 10% of ABD's volumes, is a significant threat. Despite political discussions, the state government has reaffirmed its prohibition law, ending hopes for a market return. Furthermore, rising input costs for packaging and logistics are squeezing margins across India's spirits industry. This could challenge ABD's goal of achieving 18% EBITDA margins by FY28 and strain its premium pricing. The company's historical revenue growth rate of 3.27% over five years, compared to an industry median of 15.48%, suggests potential challenges in quickly gaining market share. The substantial capital expenditure program, partly funded by a ₹1,000 crore QIP, introduces dilution risk and requires management to deliver strong returns on this invested capital. The current P/E ratio of around 60x necessitates consistent high growth, a target that could be threatened by execution errors or market challenges.

Analyst Outlook

Despite these risks, analysts maintain a largely positive outlook on Allied Blenders and Distillers, with multiple research firms issuing 'Strong Buy' ratings. Their average price target is ₹690-713, suggesting a potential upside of 17-22% from recent trading levels. Analysts forecast earnings per share (EPS) of ₹9.37 for the next fiscal year. The upcoming earnings call on May 15, 2026, will be key for investors to gauge the company's performance, the progress of its capital spending plans, and management's view amidst industry cost pressures and regulatory uncertainties.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.